Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1652645 | 0.84 | NPC1 (0.31) | RAB9A | |
| SCHEMBL10277168 | 0.82 | CRBN (0.31) | — | |
| SCHEMBL12239213 | 0.82 | PIK3CA (0.34) | — | |
| SCHEMBL10327381 | 0.80 | — | — | |
| SCHEMBL10327111 | 0.80 | ACHE (0.31) | — | |
| SCHEMBL10326927 | 0.79 | ACHE (0.33) | ALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL1035860 | 0.79 | ACHE (0.33) | ALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL15905639 | 0.79 | ACHE (0.33) | ALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL10327226 | 0.78 | POLB (0.33) | POLBRAB9AKMT2A | |
| SCHEMBL12239226 | 0.78 | BRD4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313370-B1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA LTD (GB) | 2015-08-19 | — | — | EP | disclosed |
| US-9096560-B2 | 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides | SYNGENTA LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096560-B2 | 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides | SYNGENTA LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | SYNGENTA LIMITED (GB) | 2013-02-28 | — | — | US | disclosed |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | SYNGENTA LIMITED (GB) | 2013-02-28 | — | — | US | disclosed |
| US-20110263428-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263428-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011073060-A2 | METHOD OF COMBATING AND CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010000773-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA LIMITED (GB) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263428-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | DDT, CYP1B1, AHR | ALDH1A1 50/4885POLB 4216/4885KDM4E 888/4885 |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | ACHE, ALG1, KEAP1 | ALDH1A1 386/4885POLB 4645/4885KDM4E 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.